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Abstract
LonP1 is a mitochondrial matrix protease whose selective substrate specificity is essential for maintaining mitochondrial
homeostasis. Recessively inherited, pathogenic defects in LonP1 have been previously reported to underlie cerebral, ocular,
dental, auricular and skeletal anomalies (CODAS) syndrome, a complex multisystemic and developmental disorder.
Intriguingly, although classical mitochondrial disease presentations are well-known to exhibit marked clinical heterogeneity,
the skeletal and dental features associated with CODAS syndrome are pathognomonic. We have applied whole exome se-
quencing to a patient with congenital lactic acidosis, muscle weakness, profound deficiencies in mitochondrial oxidative
phosphorylation associated with loss of mtDNA copy number and MRI abnormalities consistent with Leigh syndrome, identi-
fying biallelic variants in the LONP1 (NM_004793.3) gene; c.1693T>C predicting p.(Tyr565His) and c.2197G>A predicting
p.(Glu733Lys); no evidence of the classical skeletal or dental defects observed in CODAS syndrome patients were noted in our
patient. In vitro experiments confirmed the p.(Tyr565His) LonP1 mutant alone could not bind or degrade a substrate, consis-
tent with the predicted function of Tyr565, whilst a second missense [p.(Glu733Lys)] variant had minimal effect. Mixtures of
p.(Tyr565His) mutant and wild-type LonP1 retained partial protease activity but this was severely depleted when the
p.(Tyr565His) mutant was mixed with the p.(Glu733Lys) mutant, data consistent with the compound heterozygosity detected
in our patient. In summary, we conclude that pathogenic LONP1 variants can lead to a classical mitochondrial disease presen-
tations associated with severe biochemical defects in oxidative phosphorylation in clinically relevant tissues.
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Introduction
LonP1, the mitochondrial lon protease homologue and member
of the highly conserved AAAþ superfamily, is one of a small
group of soluble proteases in the mitochondrial matrix (1,2). On
import, the human protein is cleaved to form an approximately
100 kDa monomer that multimerizes to generate a ring-like,
functional hexamer. It has a substrate selectivity, cleaving a va-
riety of mitochondrial polypeptides and has been implicated in
proteostasis, degrading unfolded and oxidatively damaged pro-
teins (3). Further, roles as a direct binder of DNA or RNA have
also been reported (4–6). Its exact physiological role may not be
fully elucidated, but it is clear that it plays a vital function, since
a homozygous deletion of LonP1 causes early embryonic lethal-
ity in mice (7). One of its natural substrates is the mitochondrial
DNA (mtDNA) binding and packaging protein TFAM (8), which
also has a crucial role in transcription initiation and mtDNA
replication (9,10). LonP1 is therefore believed to play an essen-
tial role in mitochondrial gene expression and homeostasis (8).
Recent reports implicate pathogenic, recessively inherited
LONP1 variants in human disease phenotypes; two papers iden-
tified 11 patients with a profound and complex developmental
disorder termed CODAS (or cerebral, ocular, dental, auricular
and skeletal anomalies) syndrome (https://www.omim.org/en
try/600373; date last accessed March 13, 2018) (11,12). Patients
have a wide variety of clinical defects, some of which are com-
mon to mitochondrial disorders, such as hypotonia, short stat-
ure, brain atrophy and intellectual disability. However, there are
marked skeletal abnormalities that are not commonly associ-
ated with classic mitochondrial disease presentation which are
pathognomonic for CODAS syndrome.
Here we report the finding of compound heterozygous mis-
sense LONP1 substitutions [c.1693T>C p.(Tyr565His) and
c.2197G>A p.(Glu733Lys)] in a patient with classical mitochon-
drial disease manifestations including profound multiple
OXPHOS deficiencies associated with the quantitative loss of
mtDNA copy number in muscle. In vitro assessment of engineered
LonP1 mutants revealed that the p.(Tyr565His) mutant had only a
minimal effect on multimerization or ATP hydrolysis but was
dramatically inhibited for binding or degrading TFAM, an effect
that was partially suppressed by mixing with wild-type LonP1
protein. The second mutant, p.(Glu733Lys) had no marked effect
alone on enzyme activity, but was unable to restore function
when mixed with p.(Tyr565His) mutant protein. As segregation
studies were not possible, it cannot be formally excluded that one
of these mutations had occurred as a de novo event. However, our
data are entirely consistent with the recessive inheritance of
these variants and document for the first time that defective
LonP1 can lead to a clinical disorder more classically associated
with mitochondrial respiratory chain disease.
Results
Case report
The male proband was the second child of non-consanguineous
parents born at 40 weeks gestation in good condition; birth
weight 3490 g. At 24 h of age he presented with respiratory dis-
tress, poor feeding and a mixed acidosis with pH 6.85, pCO2 6.7
kPa, bicarbonate 4.0 mmol/l, base deficit 25.9 and plasma lac-
tate peaking at 21 mmol/l (normal range, 0.7–2.1 mmol/l). The
metabolic acidosis was managed with intravenous bicarbonate
and thiamine and biotin supplementation was introduced. He
was noted to have an apnoea and possible seizure. Subsequent
blood gases improved and enteral feeds were introduced. He
was transferred to the Regional Metabolic Centre at 7 days of
age for further investigation of the raised lactate.
Examination revealed no dysmorphic features nor organo-
megaly. Testes were undescended. The chest X-ray was normal
with no bony abnormalities and echocardiogram revealed a
structurally and functionally normal heart. Brain MRI showed a
structurally normal brain with mildly increased white matter
signal and MRS showed a lactate peak consistent with the
hyperlactataemia; median 6.3 mmol/l (range, 1.5–14.0 mmol/l)
(Supplementary Material, Fig. S1). A ketogenic diet was intro-
duced with subsequent improvement (median 2.2 mmol/l;
range 1.4–10.2 mmol/l). CPAP support was replaced with supple-
mental oxygen via nasal cannula. Episodes of respiratory dis-
tress continued and he remained nasogastric tube fed. Initial
tone was normal with good antigravity power, but paucity of
movement of the upper limbs and reduced active head move-
ments developed whilst on the unit. Muscle and skin biopsies
were taken for investigation of the congenital lactic acidosis.
His prognosis remained guarded with frequent marked
apnoeas.
Following discharge, his clinical condition gradually stabilized
with less respiratory concerns and cessation of his marked ap-
noeas. The breathing pattern remained variable with periods of
tachypnoea and bradypnoea. At 5 months of age, on review, a ve-
nous gas revealed chronic respiratory insufficiency with compen-
satory bicarbonate 31.4 mmol/l (normal range, 17–25 mmol/l).
Growth centiles at that time were 50th centile for length and be-
low the second centile for weight. There was some developmen-
tal progress, smiling at three months of age and developing hand
regard. He would babble happily but remained tube fed. He died
aged 7 months during an intercurrent upper respiratory infection.
A diagnostic muscle biopsy reveals multiple OXPHOS
deficiencies associated with severe mtDNA depletion
A diagnostic muscle biopsy was evaluated using a range of his-
topathological and biochemical assays on suspicion of sus-
pected mitochondrial disease. Haematoxylin and Eosin (H&E)
staining of transverse muscle sections revealed areas of degen-
erating muscle with inflammatory infiltrate characterized by
purple staining of nuclei clearly evident (Fig. 1Ai). The oxidative
enzyme reaction for cytochrome c oxidase (COX) activity was
weak throughout the section (Fig. 1Aii), in contrast to a rela-
tively strong succinate dehydrogenase reactivity (Fig. 1Aiii).
Sequential COX-SDH histochemistry confirmed a generalized
decrease in COX reactivity throughout the section (Fig. 1Aiv).
The spectrophotometric assessment of mitochondrial respira-
tory chain complex activities in another diagnostic centre re-
vealed low activities of complexes I and IV (normalized to
citrate synthase activity) (data not shown). The low levels of
complex I and IV activities were further supported by quadruple
immunofluorescence assays which use antibodies against porin
(mitochondrial mass), NDUFB8 (complex I) and COX1 (complex
IV) to determine relative levels of these complexes in individual
fibres across the biopsy cryosection (Fig. 1B) (13).
This severe defect, suggestive of a generalized translation
problem, was associated with severe depletion of mtDNA in pa-
tient muscle (<10% of age-matched controls; Supplementary
Material, Fig. S2). Candidate screening of SLC25A4 (NM_001151),
MPV17 (NM_002437), SUCLG1 (NM_003849), SUCLA2 (NM_003850),
TK2 (NM_004614) and RRM2B (NM_015713) was negative for
pathogenic or likely pathogenic variants, therefore prompting
WES using muscle DNA.
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Identification of rare compound heterozygous LONP1
variants
WES analysis for autosomal recessive variants in nuclear genes
encoding mitochondrial-targeted proteins prioritized only two
heterozygous missense variants in LONP1 (NM_004793.3);
c.1693T>C, p.(Tyr565His) (rs144125085) and c.2197G>A,
p.(Glu733Lys) (Fig. 1C). Both variants were absent from in-house
controls (n ¼ 378), however they were represented in heterozy-
gous form in ExAC (Exome Aggregation Consortium, http://exac.
broadinstitute.org/). The c.1693T>C, p.(Tyr565His) variant was
present in 1/118492 non-Finnish allele (MAF¼ 8.43  106), while
the c.2197G>C, p.(Glu733Lys) variant was present in 2/119658 al-
leles (MAF¼ 1.671  105), a South Asian and a non-Finnish
European. Segregation studies were not possible. Hence, to con-
firm that the two variants were present on different alleles,
amplicons were generated that spanned both variants, cloned
and eight clones were sequenced; four contained c.1693T>C,
p.(Tyr565His) alone and four contained c.2197G>C, p.(Glu733Lys)
alone (Supplementary Material, Fig. S3).
LonP1 harbours an N-terminal mitochondrial presequence
that is cleaved on entry to the mitochondrial matrix. The mature
protein has three domains: a weakly conserved N-terminal do-
main, the AAAþdomain where ATP is bound and hydrolyzed and
the C-terminal protease or P domain (Fig. 2A). The Tyr565 residue
is highly conserved (comparisons shown between human,
Bacillus subtilis and Meiothermus taiwanensis Lon proteases; Fig. 2B),
occurs in the AAAþATPase domain and the variant was pre-
dicted to be damaging to protein function (Polyphen 2; Align
GVGD; SIFT). AAAþunfoldases, of which LonP1 is a member, are
strongly evolutionarily conserved. One particular element termed
the pore loop-1, protrudes into the central, substrate binding core
of the hexamer from each subunit (14). A dipeptide aromatic-
hydrophobic (Ar-U) motif is present within this element. In the
ClpX protease, this motif is known to initially bind to the sub-
strate and be involved in transducing energy from ATP hydrolysis
to mechanical movement, effectively gripping and translocating
the substrate as it is unfolded (15,16). In human LonP1, Tyr565 is
that aromatic ortholog within the Ar-U pore-loop (Fig. 2B). There
is no atomic resolution structure of the human LonP1 available.
However, the M. taiwanensis structure is known and is well con-
served (Supplementary Material, Fig. S4). The equivalent residue
in M. taiwanensis, mTyr397 is shown in (Fig. 2C). The region
around hGlu733 is less well conserved, present near the boundary
between the AAAþATPase and protease C-terminal domain and
is not predicted to affect protein function (Fig. 2B and D). The in-
ternal pore ringed by mTyr397 residues constricts substantially
on ADP binding, illustrating this area is subject to large conforma-
tional changes (Fig. 2E).
A profound OXPHOS defect is present in muscle and
fibroblasts from the patient
Skeletal muscle lysates from the patient and controls were pre-
pared and subjected to gel electrophoresis to assess steady-
state levels of core OXPHOS proteins. As shown in Figure 3, a
profound decrease in markers for complexes I (NDUFB8), III
(CORE2) and IV (COXI, II) was apparent, whilst the complex II
marker (SDHA) was unaffected. These data are in accord with
the decreased biochemical activities noted for complex I and
complex IV and the immunohistochemical profile (Fig. 1B).
Figure 1. Muscle histopathology and identification of compound heterozygous
LONP1 variants. (A) Histochemical analysis of muscle from LonP1 patient. Serial
transverse sections (10 lm) from a muscle biopsy from the patient were sub-
jected to (i) haematoxylin and eosin staining and activity staining for (ii) cyto-
chrome c oxidase (COX) and (iii) succinate dehydrogenase (SDH). (iv) Shows
COX: SDH dual staining. Scale bar represents 50 lm. (B) Immunofluorescent
analysis of individual muscle fibres from the LonP1 patient. Skeletal muscle sec-
tions (20 lm), were subjected to quadruple immunofluorescence as described
(13). Signals were measured in individual muscle fibres from antibodies to
NDUFB8 (complex I), COX1 (complex IV) and normalized to mitochondrial mass
(porin). Each dot represents an individual muscle fibre, colour coded to repre-
sent mitochondrial mass (very low ¼ dark purple; low ¼ light purple; normal ¼
yellow; high ¼ orange). Images were used in conjunction with IMARIS software
to quantify the levels of COXI and NDUFB8 in individual fibres as described. (C)
WES analysis and filtering for rare, autosomal recessive variants in nuclear
genes encoding mitochondrial-localized proteins identified only rare heterozy-
gous LONP1 variants.
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Figure 2. Structure analysis of human and bacterial Lon variants. (A) Domain organization of H. sapiens, B. subtilis and M. taiwanensis Lon. The structure of one monomer
of the hexameric M. taiwanensis Lon is shown (PDB ID: 4YPL). The N-terminal domain is shown in green, AAAþATPase domain in blue and protease domain in orange.
All three variants show similar domain organization, with the human variant containing an additional mitochondrial targeting sequence (MTS, grey). The predicted lo-
cation of the two variants in human Lon, hTyr565His and hGlu733Lys, are shown as black and magenta spheres, respectively. (B) Sequence alignments of human and
bacterial Lon are shown around the two variants, Tyr565 and Glu733. (C) Analysis of internal channels of M. taiwanensis Lon revealed a large internal cavity leading
from the substrate binding site to the protease domain. The M. taiwanensis hTyr565 equivalent, mTyr397, is located at the entrance to this channel and protrudes di-
rectly into the cavity. (D) The bacterial hGlu733 equivalent, mGlu564, is located on a loop in close proximity to mArg519 and mTrp558. This may allow for a stabilizing
salt-bridge interaction. (E) Model to illustrate the large conformational change that occurs on ADP binding. Large structural differences are observed in ADP-free (blue)
and ADP-bound (green) subunits of M. taiwanensis Lon (PDB ID: 4YPL). The bacterial Tyr565 equivalent, mTyr397, forms part of the conserved Ar-U pore-loop (Tyr-Val/
Ile) implicated in substrate binding and translocation. The tyrosine residues are shown as orange (ADP-free state) or red (ADP-bound state) spheres in the top-down
view.
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Additionally, the major mitochondrial transcription and replica-
tion factor, TFAM, was also depleted in patient muscle, consis-
tent with the observation of severe mtDNA depletion. LonP1
levels were mildly increased in the patient sample. A fibroblast
cell line from the patient was established and extract analysed
by both non-denaturing blue native and denaturing gel electro-
phoresis (Fig. 3A and B). Substantial decreases were shown for
intact complex I and IV levels and a decrease in the steady-state
level of NDUFB8, COXI and COXII were also apparent. Levels of
TFAM in fibroblasts were unaffected, although contrary to the
skeletal muscle sample the patient cell line had a>2-fold in-
crease in mtDNA copy number (patient, 1060617 n¼ 6; control
1, 5696 15 n¼ 6; control 2, 417626; n¼ 5).
Neither LONP1 mutant markedly affects oligomer
formation
To determine pathogenicity of both LONP1 variants we at-
tempted to reconstitute the mutant LonP1 forms in vitro and as-
sess the effects of the variants on LonP1 functions. Mature
proteins containing either the p.(Tyr565His) or p.(Glu733Lys)
substitutions and harbouring a short C-terminal His tag to facili-
tate purification were expressed and purified along with a simi-
lar wild-type version. First, each of the LonP1 forms was
assessed for their ability to form oligomers by comparing their
mobility against defined molecular weight standards on a gel fil-
tration column. As shown in Figure 4, high salt (1 M NaCl) and
absence of ATP cofactor largely prevented the formation of
higher order oligomer (Fig. 4A, top three panels; Fig. 4B, left
panel), irrespective of whichever form of LonP1 was assessed.
However, at low salt concentration and in the presence of ATP,
multimers were favoured for all LonP1 forms (Fig. 4a, bottom
three panels; Fig. 4B, right panel).
Figure 3. OXPHOS proteins are markedly depleted in LonP1 patient skeletal mus-
cle and fibroblasts. (A) Western blot analysis of skeletal muscle and fibroblast
extracts in patient and controls. Lysates (skeletal muscle, 30 lg; fibroblast, 40 lg)
from different controls (skeletal muscle, lanes 1, 2; fibroblasts, lane 4, 5, 6) or pa-
tient (skeletal muscle, lane 3; fibroblasts, lane 7) were subjected to western blot
analysis with antibodies to the indicated proteins as described. The relevant
OXPHOS complex is shown in italics. TFAM is shown for fibroblasts lysates to-
gether with loading control derived from a separate blot. (B) BN-PAGE analysis
of fibroblast extracts (100 lg) from two separate controls (lane 1, 2) or patient
(lane 3) was performed as detailed. Each complex was visualized by the subunit-
specific antibody indicated.
Figure 4. Multimerization comparisons and scanning fluorimetry. (A) The oligo-
meric states of LonP1 wild-type, p.(Tyr565His) and p.(Glu733Lys) were separated
on a gel filtration column and resolved by SDS-PAGE. Samples were analysed in
low salt (50 mM NaCl) and high salt (1 M NaCl) conditions without or with 4 mm
ATP, respectively. The hexameric and monomeric fractions are indicated based
on a size calibration curve. I, input; Mw, molecular size marker. (B)
Densitometric analysis of the fractions shown in (A) with 1 M NaCl and without 4
mM ATP (left panel) or 50 mM NaCl supplemented with 4 mm ATP (right panel).
(C) Mutation-induced loss of LonP1 activity is not associated with global struc-
tural defects. Melting of various LonP1 forms (1.6 mM) was measured by differen-
tial scanning fluorometry in the presence of sypro orange 64 mM ATP as
described in Materials and Methods. Melting temperatures (Tm), were calculated
from the first derivative of fluorescence intensity against time and are shown
for each LonP1 form.
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To confirm that either of the two variants did not cause any
global structural defects, each oligomer was subjected to differ-
ential scanning fluorimetry in the presence and absence of 4
mM ATP (Fig. 4C). A modest ATP-induced stabilization was ob-
served (DTm 2–3C) for all complexes, although no significant
difference was seen between wild-type and mutant LonP1
proteins.
The p.(Tyr565His) LONP1 mutant ablates proteolytic
activity
The rates of ATP hydrolysis of the three LonP1 forms were as-
sessed using the Malachite Green Phosphate assay. As shown in
Figure 5A and Table 1, rates were not significantly different be-
tween the three forms although total ATPase activity was
higher for the p.(Tyr565His) mutant. The addition of the LonP1
protein substrate TFAM did not measurably affect ATP hydroly-
sis rates of any of the three forms (data not shown). Next, to de-
termine whether the variants caused any modulation of
protease activity, degradation assays were performed over a 75
min time course with TFAM as substrate. On ATP addition,
strong proteolytic activity was noted for the wild-type and
p.(Glu733Lys) forms (Fig. 5B and C and Table 1). However, there
was negligible activity for p.(Tyr565His). Thus, p.(Tyr565His) is
essentially catalytically inactive despite being capable of ATP
hydrolysis.
The p.(Tyr565His) LONP1 mutant prevents binding to
TFAM substrate
Previous reports have suggested that by mutating the Ar-U
pore-loop in certain AAAþ family proteins, substrate binding
was attenuated (14,15,17–19). To assess binding of TFAM to each
of the LonP1 forms, TFAM was fluorescently labelled and micro-
scale thermophoresis performed in the presence of ATP or the
non-hydrolyzable ATP analogue AMP-PMP (Fig. 6). Low micro-
molar range binding affinities were apparent between TFAM
substrate and either wild-type (1.36 60.09 lM) or p.(Glu733Lys)
(1.52 60.1 lM) in buffer. An interaction between TFAM and
p.(Tyr565His) LonP1 could not be detected under any of the con-
ditions tested. The addition of ATP (Fig. 6B) resulted in substrate
degradation and subsequent loss of fluorescent signal for wild-
type and p.(Glu733Lys) LonP1 which made assessment of bind-
ing affinity impossible. Surprisingly AMP-PNP had little effect,
marginally weakening the affinity for the two binders. This sug-
gests that TFAM can interact with wild-type and p.(Glu733Lys)
LonP1 without the necessity for ATP hydrolysis.
Mixed mutant oligomers are severely attenuated for
substrate binding and proteolysis
Data confirms the p.(Tyr565His) LonP1 mutant is unable to bind
a model substrate, TFAM, and is consequently catalytically at-
tenuated. By contrast, evidence to date suggested that the
p.(Glu733Lys) mutant may have been a neutral polymorphism,
as there was no appreciable effect on hexamer formation and
the homohexamer was efficient in TFAM binding and proteoly-
sis. Nevertheless, our in vitro experiments had yet to recapitu-
late the physiological situation for either parent or the proband,
as genetic evidence indicated a mix of two forms of LonP1 in all
cases: mutant and wild-type allele for each unaffected parent
and the two mutant forms for the patient. To produce the mixed
oligomers, equimolar amounts of various permutations of two
LonP1 forms were added together in high salt to produce mono-
mers before oligomerization was induced by dialysis. Following
dialysis, aliquots of each mixture were assessed by gel filtration
to confirm successful oligomerization and homo-oligomers
were also reformed for WT (Supplementary Material, Fig. S5)
and p.(Glu733Lys) to confirm the process did not itself cause
loss of activity (Supplementary Material, Fig. S6). Mixtures were
then subjected to TFAM-binding and proteolysis assays per-
formed as detailed above (Fig. 7). When wild-type and
p.(Glu733Lys) forms were mixed, binding was slightly weakened
(WT 1.36 6 0.09 lM cf. WT/E733K 2.176 0.12 lM), consistent with
a partial reduction in TFAM degradation activity (13% remaining
TFAM after 45 min cf. 21% for WT/E733K; Table 1). When wild-
type and the catalytically inactive p.(Tyr565His) mutant were
mixed, TFAM-binding affinity was reduced (3.22 6 0.17 lM).
Unlike the p.(Tyr565His) mutant alone, however, protease activ-
ity was detected albeit reduced from WT (13% remaining TFAM
after 45 min cf. 43% for WT/Y565H; Table 1). Both sets of data
suggest this lower level of LonP1 activity was sufficient to as-
sure an absence of clinical presentation for either parent who
Figure 5. The p.(Tyr565His) mutant hydrolyzes ATP efficiently but is massively
impaired in proteolytic activity. (A) ATP hydrolysis assays. The three LonP1
forms (2 lg) were measured for ATP hydrolytic activity during a 60 min time
course as described. Data were fit to an exponential growth to maximum from
which the pseudo first-order rate constant was calculated. (B) Proteolysis assays.
The LonP1 substrate, TFAM, was incubated in the presence of 2 mM ATP supple-
mented with BSA and with either of the two LonP1 mutants (left panels) or wild-
type (right panel). Aliquots were taken over a 75 min time course and separated
through a precast 4–20% denaturing acrylamide gradient gel before visualization
and densitometry. (C) Data from (B) were fit to an exponential decay using least
squares non-linear regression analysis.
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had a wild-type allele in tandem with either of the mutant
LonP1 alleles. Interestingly, although the p.(Glu733Lys) LonP1
homohexamer had shown no defect in activity, it was partially
affected when mixed together with the wild-type LonP1 (Fig. 7A
and B). When mixed with the catalytically inactive p.(Tyr565His)
mutant, a dramatic attenuation in both substrate binding and
proteolysis was seen (Table 1). These data are consistent with
the profound clinical phenotype in the patient being due to the
loss of LonP1 activity and confirming pathogenicity of the com-
pound heterozygous c.1693T>C p.(Tyr565His) and c.2197G>A
p.(Glu733Lys) variants.
Discussion
Recessively inherited LONP1 variants have been previously
linked to CODAS syndrome (https://www.omim.org/entry/
600373), a unique disorder with distinctive clinical anomalies
(11,12). Although the CODAS acronym signifies cerebral, ocular,
dental, auricular and skeletal anomalies syndrome, reported pa-
tients appear to manifest a broad-spectrum of phenotypes rang-
ing from isolated paediatric cataracts to severe CODAS-plus
syndrome. This complex syndrome shares several clinical
features of ‘classical’ mitochondrial disorders including intellec-
tual disability, short stature, hypotonia and ptosis. However,
there are skeletal and dental anomalies that are pathognomonic
for CODAS syndrome. Recently, one individual presenting atypi-
cal CODAS syndrome with myopathy resembling Marinesco–
Sjo¨gren syndrome was described (20). Furthermore, a
c.2014C>T, p.(Arg627Cys) LONP1 variant has also been impli-
cated in causing both CODAS syndrome and isolated paediatric
cataracts (21).
By contrast, we identified rare biallelic variants in LONP1,
c.1693T>C, p.(Tyr565His) and c.2197G>A, p.(Glu733Lys), in a
patient presenting with congenital lactic acidosis, muscle weak-
ness and brain MRI typical of Leigh syndrome, who had pro-
found OXPHOS deficiencies and severe mtDNA depletion in
skeletal muscle. Pathogenic LONP1 variants have been reported
at various positions throughout the protein, although most are
typically located in the ATPase and proteolytic-domains.
Several CODAS syndrome-linked variants are in close proximity
to the identified c.2197G>A, p.(Glu733Lys) variant, including
c.2161C>G, p.(Arg721Gly), c.2171C>T, p.(Ala724Val) and
c.2245C>T, p.(Pro749Ser). Contrastingly, the c.1693T>C,
p.(Tyr565His) variant also occurs in the ATPase domain but in
the Ar-U pore-loop and is not proximal to other previously re-
ported pathogenic variants. Taken together, the clinical presen-
tation of our proband and in vitro studies suggest that the
c.1693T>C, p.(Tyr565His) and c.2197G>A, p.(Glu733Lys) vari-
ants are unique. Thus, this supports an expanding clinical spec-
trum of LONP1-related disorders.
Our in vitro data provide compelling evidence that the
c.1693T>C, p.(Tyr565His) variant causes profound defects in
both LonP1 substrate binding and proteolytic activity. This
highly conserved residue in the dipeptide domain of pore loop-1
has been found in numerous structural studies of similar
AAAþunfoldases/proteases to line the internal pore of the
Table 1. Catalytic activity of wild-type and mutant LonP1
LonP1 form ATP hydrolysisa TFAM degradationb
Maximal activity (pmol Pi formed) Rate constant (min1) TFAM remaining (%)c Rate constant (min1)
WT 1394.8 6 24.2 0.126 0.008 12.9 6 1.5 0.05 6 0.01
Y565H 2043.9 6 20.4 0.156 0.005 99.1 6 1.5 0.003 6 0.001
E733K 1179.7 6 12.6 0.116 0.004 9.9 6 4.3 0.11 6 0.01
WT þ Y565H ND ND 42.9 6 3.1 0.02 6 0.003
WT þ E733K ND ND 20.8 6 2.3 0.03 6 0.003
Y565H þ E733K ND ND 75.6 6 0.4 0.009 6 0.001
ND, not determined.
aData fit to: y¼a*(1  exp(b*x)), where a is the maximum value of y and b is the apparent rate constant.
bData fit to: y¼ y0þ a*exp(b*x), where y0 is the value of y at time 0, a is the minimum value of y and b is the apparent rate constant.
cData shown are the % TFAM remaining after 45 min incubation compared with the 0 min control.
Figure 6. The p.(Tyr565His) mutant displays severe substrate binding defects. The binding interaction between LonP1 (4.65 mM) and its TFAM substrate (100 nM) was ana-
lysed by microscale thermophoresis as described above in buffer (A), 4 mM ATP (B) or 4 mM AMP-PNP (C). The equilibrium dissociation constant, Kd (lM) is given for each
binding pair in parenthesis. NM: not measurable.
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hexamer (15,22). It has been shown to interact directly with the
substrate, and the coordinated concurrent large conformational
changes around the ring of monomers, which occurs on ATP hy-
drolysis, results in translocation and unfolding of substrate that
is necessary for proteolytic degradation (15). It is therefore en-
tirely consistent with the biochemical data reported above that
this variant is pathogenic. TFAM binding and proteolytic degra-
dation were unmeasurable, whilst formation of hexamer was
not significantly affected and the hexamer was as thermally
stable as the wild-type LonP1. Mixing the wild-type and
p.(Tyr565His) LonP1 monomers prior to hexamer formation re-
sulted in weaker affinity for TFAM and a decreased rate of deg-
radation but represented a substantial increase over
p.(Tyr565His) alone. We cannot determine from our experi-
ments whether this is due to mixed heterohexamers having re-
duced activity or whether the mutant somehow blocked mixed
hexamer formation with the wild-type monomer, resulting
mainly in two discrete populations of homohexamer. However,
this weaker but clearly present activity was consistent with the
recessive nature of the variant.
Predicting the effect of the second variant, c.2197G>A,
p.(Glu733Lys), from structural data is more complex. The resi-
due is not completely conserved and is found immediately N-
terminal to a short beta sheet (b9) at the end of the
AAAþdomain and prior to the protease domain linker.
Pathogenic variants at this site have never previously been im-
plicated in pathogenesis. This substitution in the homohexamer
does not significantly reduce ATP hydrolysis, TFAM binding or
proteolytic function in vitro. However, when p.(Glu733Lys) is
mixed with wild-type LonP1, activity is diminished (Fig. 5B and
C cf Fig. 7A and B) and when mixed with the p.(Tyr565His) mu-
tant there is a profound decrease in activity. Clearly, the
p.(Glu733Lys) mutant also has a negative impact on LonP1 activ-
ity but the negative effect is somehow rescued if all monomers
in the hexamer contain the substitution. The reason for this re-
mains unclear, although it is consistent with the genetics of the
family. This may be attributed to local structural deformations
around the mutated residue. For the p.(Glu733Lys) LonP1 mu-
tant alone, the effects of this deformation may be neutralized
due to its presence in all subunits of the homohexamer.
However, when p.(Glu733Lys) is mixed with wild-type or
p.(Tyr565His) LonP1, the resulting heterohexamers may no lon-
ger be capable of this rescue due to conformational differences
between adjacent subunits. Whereas wild-type subunits would
be able to partially rescue the activity of a Tyr565-containing
p.(Glu733Lys) LonP1, the p.(Tyr565His) mutant—which cannot
bind or translocate substrate—would not. This is consistent
with observations in E. coli ClpX (15), where removal of even a
few pore loop tyrosine residues lead to a loss of substrate
binding.
Finally, we were able to observe that loss of LonP1 activity
led to a massive decrease in respiratory chain complex activity
in patient skeletal muscle. This is entirely consistent with the
depletion of mtDNA, which encodes key components of these
respiratory chain complexes. Why, however, does the absence
of LonP1 activity lead to mtDNA depletion? The exact
Figure 7. Mixed LonP1 mutant hexamers have severe TFAM binding and proteolytic defects. Hexameric mixtures (1: 1) of all LonP1 forms were prepared by dialysing
the monomers from high salt as described above. (A) TFAM degradation assays were performed as described in the legend to Figure 4 with mixtures of wild-type and ei-
ther of the two mutant forms (left panels) or with a mixture of both wild-type monomers (right). Amounts of remaining intact TFAM were calculated and fit to an expo-
nential decay using least squares non-linear regression analysis (B). In (C), the binding between the mixtures of LonP1 and TFAM substrate in the presence of AMP-PNP
were estimated by microscale thermophoresis. The equilibrium dissociation constant, Kd (lM) is given for each binding pair in parenthesis. NM; not measurable.
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connection is unclear. LonP1 has been shown to regulate
mtDNA copy number in Drosophila melanogaster by cleaving
TFAM (8). It is known that TFAM and mtDNA have a mutual de-
pendence for stability, whereby TFAM binds mtDNA and pro-
tects it from degradation, but when not bound to mtDNA, TFAM
is rapidly degraded (9). Whilst LonP1-mediated TFAM degrada-
tion may have an acute role in regulating mtDNA levels by caus-
ing the loss of excess TFAM and thus reducing mtDNA levels, it
cannot fully explain the observation in this patient. It has been
demonstrated that small changes in TFAM levels dramatically
impact the fraction of mtDNA molecules available for transcrip-
tion and DNA replication. At high TFAM/DNA ratio TFAM forms
stable protein filaments on DNA that block melting and prevent
progression of the replication and transcription machineries
(23). Therefore, failure to reduce TFAM levels may inhibit
mtDNA replication and explain the mtDNA depletion seen in
the patient. The mtDNA depletion itself would, in turn, explain
the decrease in TFAM level. Further, LonP1 is not a non-specific
protease but it has numerous known protein substrates in the
mitochondrial matrix. It is highly likely that the absence of
LonP1 activity will have many pleiotropic effects, one of which
must result in the chronic loss of mtDNA content.
Materials and Methods
Whole exome sequencing, analysis and interpretation
Exome capture of fragmented genomic DNA from muscle was
attained using the Illumina TruSeq Rapid Exome (45 Mb) cap-
ture kit, sequenced using the Illumina HiSeq 2000 platform in
100 bp reads and aligned to the human reference genome (UCSC
hg38). Called variants were restricted to exonic (coding) or
splice-site variants with a minor allele frequency (MAF) less
than or equal to 0.01 (1%) from 378 in-house controls and exter-
nal variant databases, including ExAC and the 1000 Genomes
Project. Autosomal recessive (homozygous or compound het-
erozygous) variants in nuclear genes encoding mitochondrial-
targeted proteins were prioritized. Pathogenicity of missense
variants was assessed using Polyphen 2 (http://genetics.bwh.
harvard.edu/pph2/), Align GVGD (http://agvgd.hci.utah.edu/)
and SIFT (http://sift.jcvi.org/). Identified candidate variants were
validated by Sanger sequencing.
Histopathological and biochemical analyses of OXPHOS
function
Routine histological and histochemical analyses of skeletal
muscle cryosections (10 lm) were undertaken as part of the di-
agnostic work-up. The activities of the respiratory chain com-
plexes and the matrix marker enzyme, citrate synthase, were
determined as described previously (24). Quantitative immuno-
fluorescence analysis of frozen skeletal muscle cryosections
was undertaken to assess the levels of OXPHOS complexes I
(anti-NDUFB8) and IV (anti-COXI) relative to a marker of mito-
chondrial content (anti-VDAC1) essentially as described (13).
Cell culture
Primary paediatric control and LONP1 patient fibroblasts were
cultured in Eagle’s minimal essential medium (Sigma Aldrich)
supplemented with 10% (v/v) fetal calf serum, 1 non-essential
amino acids, 1 mM sodium pyruvate and 50 mg/ml uridine. Cell
lines were propagated at 37C in humidified 5% CO2.
Protein extract production, western blot and blue native
gel analyses
For total protein extraction from muscle, frozen age-matched
control or patient muscle tissue (10 mg) was crushed in RIPA
buffer [1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1%
EDTA, 10 mM b-mercaptoethanol, 10 mg/ml PMSF, 15 ml/ml Triton
X-100, 1 EDTA-free protease inhibitor (Pierce)]. The homoge-
nate was vortexed, incubated on ice and then homogenized
with the T25 Ultra-Turrax homogenizer (IKA). Homogenates
were centrifuged at 14 000g, 10 min, 4C and the supernatants
retained. For cultured cell extracts, fibroblasts were harvested
and lysed in 50 mM Tris–HCl pH 7.5, 130 mM NaCl, 2 mM MgCl2, 1
mM PMSF, 1% NP-40 and 1 EDTA-free protease inhibitor cock-
tail (Pierce). Protein lysates were separated on 12% polyacrylam-
ide gels using SDS-PAGE and transferred to a PVDF membrane
via electrophoresis. The membranes were blocked in 5% milk/
TBS-T and immunoblotted using primary and HRP-conjugated
secondary antibodies. Extraction of mitochondrial membranes
and Blue-native polyacrylamide-gel electrophoresis (BN-PAGE)
analysis was performed according to previously described
methodologies (25). Briefly, mitochondrial extracts were solubi-
lized with n-dodecyl b-D-maltoside (Sigma) and 100 mg of control
and patient samples were electrophoretically separated on a
4–16% native polyacrylamide BisTris gradient gel (Life
Technologies). Complexes were transferred onto PVDF mem-
branes and subjected to immunoblotting with primary antibod-
ies: NDUFB8 (complex I), SDHA (complex II), UQCRC2 (complex
III), COXI (complex IV), and ATP5A (complex V).
The following primary antibodies were sourced as follows:
OXPHOS Human Cocktail (Abcam, ab110411), NDUFB8 (Abcam,
ab110242), SDHA (Abcam, ab14715), CORE2 (Invitrogen, A11143),
COXI (Abcam, ab14705), COXII (Abcam, ab110258), ATP5A (Life
Technologies, 7F9BG1), LONP1 (Sigma, HOA002192), TFAM
(Abcam, ab119684), VDAC1 (Abcam, ab14734) and b-actin
(Sigma, A1978).
Production of LonP1 forms, expression and purification
Wild-type LonP1 lacking the mitochondrial targeting sequence
[1–114; (26)] was cloned into a pET-20b vector with a 6X His tag
at the C-terminus. LonP1 variants were generated using the
QuickChange Lightning site-directed mutagenesis kit
(Stratagene) according to the manufacturer’s instructions.
Protein expression was induced with 1 mM IPTG at 37C for 2.5
h. Cells were subsequently harvested, frozen in liquid nitrogen
and thawed at 4C in lysis buffer containing 25 mM Tris–HCl pH
8.0, 10 mM b-mercaptoethanol and 1protease inhibitors. Cells
were then lysed using an Ultra-Turrax T3 homogenizer (IKA)
and supernatant was loaded onto a His-Select Nickel Affinity
Gel (Sigma-Aldrich) equilibrated with 20 mM imidazole in buffer
A (25 mM Tris–HCl, pH 8.0, 0.4 M NaCl, 10% glycerol, 10 mM b-mer-
captoethanol and 1protease inhibitors) followed by elution by
250 mM imidazole in buffer A. Proteins were subsequently puri-
fied over a 5 ml HiTrap Heparin column (GE Healthcare) and a 1
ml HiTrap MonoQ column (GE Healthcare). Both HiTrap col-
umns were equilibrated in buffer B (20 mM Tris–HCl, pH 8.0, 0.1 M
NaCl, 10% glycerol, 0.5 mM EDTA and 1 mM DTT) and the pro-
teins were eluted by a salt gradient (0.2–1.2 M NaCl in buffer B).
Lastly, proteins were purified over a HiLoad 16/60 Superdex 200
gel filtration column (GE Healthcare) equilibrated in buffer C (20
mM Tris–HCl, pH 8.0, 0.4 M NaCl, 10% glycerol and 2 mM DTT).
The purity of the protein was estimated by SDS-polyacrylamide
gel electrophoresis and Coomassie Brilliant Blue staining.
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Microscale thermophoresis
TFAM was cysteine labelled using a 2-fold excess of NT-547-
maleimide dye according to the manufacturer’s instructions.
Twelve two-fold dilutions of unlabelled LonP1 or 1: 1 mixtures
of WT/p.(Tyr565His), WT/p.(Glu733Lys) or p.(Tyr565His)/
p.(Glu733Lys) (2.3–4650 nM) were made in MST buffer (50 mM
Tris–HCl, pH 8.0, 10 mM MgCl2, 10% glycerol) supplemented with
4 mM ATP or AMP-PNP. Dilutions were incubated with 200 nM la-
belled TFAM for 10 min at 24C. Samples were analysed in tripli-
cate using a Monolith NT.115 instrument (NanoTemper
Technologies, Munich, Germany) with standard capillaries, 80%
LED power and 60% MST power for 30 s at 24C. Thermophoresis
data were baseline corrected and used to calculate Kd, bound
state and unbound state in the NanoTemper analysis software.
The standard error was calculated from three independent
measurements.
Oligomerization assay/gel filtration analysis
Hexamerization of wild-type, p.(Tyr565His) and p.(Glu733Lys)
LonP1 was monitored by gel-filtration chromatography using a
Superose 6 Increase 10/300 column (GE Healthcare) pre-
equilibrated in running buffer A (20 mM Tris–HCl, pH 8.0, 10%
glycerol, 2 mM DTT, 1 M NaCl) or B (20 mM Tris–HCl, pH 8.0, 10%
glycerol, 2 mM DTT, 50 mM NaCl and 10 mM MgCl2). Each protein
was dialyzed into running buffer A or B with buffer B samples
incubated at 37C for 10 min in the presence of 1 mM ATP.
Samples (200 ml) were injected onto the column with a flow rate
of 200 ml/min and monitored by absorbance at 280 nm. Fractions
of 250 ml were collected, analysed by SDS-PAGE and bands quan-
tified using ImageLab software (BioRad). A size calibration curve
was prepared using thyroglobulin (670 kDa), c-globulin (158
kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B12
(1.35 kDa) according to the manufacturer’s instructions
(BioRad). All samples were analysed in triplicate and represen-
tative gels shown.
Thermofluor stability assay
The fluorescent dye Sypro Orange (Invitrogen) was used to mon-
itor the temperature-induced unfolding of wild-type and mu-
tant LonP1. Wild-type and mutant proteins (1.6 mM final) were
set up in 96 well PCR plates in assay buffer (50 mM Tris–HCl, pH
8 and 50 mM NaCl) in the absence or presence of 4 mM ATP.
Differential scanning fluorimetry was performed in a C1000
Thermal Cycler using the CFX96 real time software (BioRad).
Scans were recorded using the HEX emission filter (560–580 nm)
between 4 and 95C in 0.5C increments with a 5 s equilibration
time. The melting temperature (Tm) was determined from the
first derivative of a plot of fluorescence intensity versus temper-
ature (27). The standard error was calculated from three inde-
pendent measurements.
Protein structure modelling
The structure of the Meiothermus taiwanensis LonA protease (PDB
ID: 4YPL) was used to model the effects of the human
p.(Tyr565His) and p.(Glu733Lys) variants in PyMol (The PyMol
Molecular Graphics System, Version 2.0, Schro¨dinger, LLC). The
equivalent M. taiwanensis residues were identified by sequence
alignment of the human and bacterial Lon proteins in Clustal
Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/; date last
accessed March 13, 2018). Analysis of internal cavities was per-
formed using the 3V server with default settings (28).
ATP hydrolysis assay
In vitro ATPase assays were performed using the Malachite
Green Phosphate Assay kit (BioAssay systems, POMG-25H) ac-
cording to manufacturer’s instructions. Briefly, samples were
prepared6 ATP with 2 mg recombinant LonP1 in a total volume
of 20 ml per reaction. A standard curve (0–40 mM phosphate) was
also prepared in triplicate. The samples were incubated at 37C
for 0–60 min and the reaction stopped by addition of 80 ml work-
ing reagent. Samples were loaded onto Nunclan 96-well flat
transparent plates and incubated at room temperature for 25
min followed by measurement A630 nm on the Tecan Infinite
M200 using Magellan 6 software. Standard error was calculated
from three independent measurements.
TFAM proteolysis assay
In vitro TFAM proteolysis assays were performed in 10 ml reac-
tions with 9.5 pmol recombinant LonP1 protein,66.5 pmol
TFAM and 2 buffer (100 mM NaCl, 50 mM Tris–HCl, pH 8, 10 mM
MgCl2, 0.1 mg/ml BSA) with or without 2 mM ATP. Recombinant
LonP1 and TFAM proteins were diluted in 2 buffer without ATP
if necessary. The samples were incubated at 37C for 0–75 min,
respectively and then immediately placed on ice. Samples were
separated on a precast 4–20% gradient SDS-PAGE gel (BioRad,
567–8094) and visualized on a ChemiDoc MP Imager using
ImageLabTM (BioRad) to determine the efficiency of TFAM
degradation.
Supplementary Material
Supplementary Material is available at HMG online.
Acknowledgements
We thank Dr Ata Siddiqui for the MRI/MRS figure and associated
interpretation.
Conflict of interest statement. None declared.
Funding
This study was supported by funding from the Wellcome Centre
for Mitochondrial Research (203105/Z/16/Z) (R.N.L., Z.M.A.C.L.
and R.W.T.) and Swedish Research Council grants to M.F. (2013–
3621), the Swedish Cancer Foundation to M.F. (CAN 2016/816)
and the European Research Council to M.F. (DELMIT). R.W.T.
also receives support from the MRC Centre for Neuromuscular
Diseases (G0601943), the UK NHS Highly Specialized ‘Rare
Mitochondrial Disorders of Adults and Children’ Service and the
Lily Foundation. R.N.L. and Z.M.A.C.L. would like to thank
Rawaa Al-Faresi for help with cloning and sequencing. E.W.S.
was supported by a Medical Research Council (MRC) funded PhD
studentship. Funding to pay the Open Access publication
charges for this article was provided by Wellcome.
References
1. Arnold, I. and Langer, T. (2002) Membrane protein degrada-
tion by AAA proteases in mitochondria. Biochim. Biophys.
Acta, 1592, 89–96.
10 | Human Molecular Genetics, 2018, Vol. 00, No. 00
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy080/4922471
by University of Newcastle user
on 19 April 2018
2. Gerdes, F., Tatsuta, T. and Langer, T. (2012) Mitochondrial
AAA proteases–towards a molecular understanding of
membrane-bound proteolytic machines. Biochim. Biophys.
Acta, 1823, 49–55.
3. Bota, D.A. and Davies, K.J. (2016) Mitochondrial Lon protease
in human disease and aging: including an etiologic classifi-
cation of Lon-related diseases and disorders. Free Radic. Biol.
Med., 100, 188–198.
4. Fu, G.K. and Markovitz, D.M. (1998) The human LON protease
binds to mitochondrial promoters in a single-stranded, site-s-
pecific, strand-specific manner. Biochemistry, 37, 1905–1909.
5. Liu, T., Lu, B., Lee, I., Ondrovicova, G., Kutejova, E. and
Suzuki, C.K. (2004) DNA and RNA binding by the mitochon-
drial lon protease is regulated by nucleotide and protein sub-
strate. J. Biol. Chem., 279, 13902–13910.
6. Chen, S.H., Suzuki, C.K. and Wu, S.H. (2007) Thermodynamic
characterization of specific interactions between the human
Lon protease and G-quartet DNA. Nucleic Acids Res., 36,
1273–1287.
7. Quiros, P.M., Espanol, Y., Acin-Perez, R., Rodriguez, F.,
Barcena, C., Watanabe, K., Calvo, E., Loureiro, M., Fernandez-
Garcia, M.S., Fueyo, A. et al. (2014) ATP-dependent Lon prote-
ase controls tumor bioenergetics by reprogramming mito-
chondrial activity. Cell Rep., 8, 542–556.
8. Matsushima, Y., Goto, Y. and Kaguni, L.S. (2010)
Mitochondrial Lon protease regulates mitochondrial DNA
copy number and transcription by selective degradation of
mitochondrial transcription factor A (TFAM). Proc. Natl. Acad.
Sci. U. S. A., 107, 18410–18415.
9. Ekstrand, M.I., Falkenberg, M., Rantanen, A., Park, C.B.,
Gaspari, M., Hultenby, K., Rustin, P., Gustafsson, C.M. and
Larsson, N.G. (2004) Mitochondrial transcription factor A reg-
ulates mtDNA copy number in mammals. Hum. Mol. Genet.,
13, 935–944.
10. Gustafsson, C.M., Falkenberg, M. and Larsson, N.G. (2016)
Maintenance and expression of mammalian mitochondrial
DNA. Annu. Rev. Biochem., 85, 133–160.
11. Dikoglu, E., Alfaiz, A., Gorna, M., Bertola, D., Chae, J.H., Cho,
T.J., Derbent, M., Alanay, Y., Guran, T., Kim, O.H. et al. (2015)
Mutations in LONP1, a mitochondrial matrix protease, cause
CODAS syndrome. Am. J. Med. Genet. A, 167, 1501–1509.
12. Strauss, K.A., Jinks, R.N., Puffenberger, E.G., Venkatesh, S.,
Singh, K., Cheng, I., Mikita, N., Thilagavathi, J., Lee, J.,
Sarafianos, S. et al. (2015) CODAS syndrome is associated
with mutations of LONP1, encoding mitochondrial AAAþ
Lon protease. Am. J. Hum. Genet., 96, 121–135.
13. Rocha, M.C., Grady, J.P., Grunewald, A., Vincent, A., Dobson,
P.F., Taylor, R.W., Turnbull, D.M. and Rygiel, K.A. (2015) A novel
immunofluorescent assay to investigate oxidative phosphory-
lation deficiency in mitochondrial myopathy: understanding
mechanisms and improving diagnosis. Sci. Rep., 5, 15037.
14. Yamada-Inagawa, T., Okuno, T., Karata, K., Yamanaka, K.
and Ogura, T. (2003) Conserved pore residues in the AAA
protease FtsH are important for proteolysis and its coupling
to ATP hydrolysis. J. Biol. Chem., 278, 50182–50187.
15. Martin, A., Baker, T.A. and Sauer, R.T. (2008) Pore loops of the
AAAþ ClpX machine grip substrates to drive translocation
and unfolding. Nat. Struct. Mol. Biol., 15, 1147–1151.
16. Sauer, R.T. and Baker, T.A. (2011) AAAþ proteases:
aTP-fueled machines of protein destruction. Annu. Rev.
Biochem., 80, 587–612.
17. Hinnerwisch, J., Fenton, W.A., Furtak, K.J., Farr, G.W. and
Horwich, A.L. (2005) Loops in the central channel of ClpA
chaperone mediate protein binding, unfolding, and translo-
cation. Cell, 121, 1029–1041.
18. Okuno, T., Yamanaka, K. and Ogura, T. (2006)
Characterization of mutants of the Escherichia coli AAA prote-
ase, FtsH, carrying a mutation in the central pore region. J.
Struct. Biol., 156, 109–114.
19. Graef, M. and Langer, T. (2006) Substrate specific
consequences of central pore mutations in the i-AAA protease
Yme1 on substrate engagement. J. Struct. Biol., 156, 101–108.
20. Inui, T., Anzai, M., Takezawa, Y., Endo, W., Kakisaka, Y.,
Kikuchi, A., Onuma, A., Kure, S., Nishino, I., Ohba, C. et al.
(2017) A novel mutation in the proteolytic domain of LONP1
causes atypical CODAS syndrome. J. Hum. Genet., 62, 653–655.
21. Khan, A.O., Aldahmesh, M.A. and Alkuraya, F.S. (2015)
Phenotypes of recessive pediatric cataract in a cohort of chil-
dren with identified homozygous gene mutations (an
American Ophthalmological Society thesis). Trans. Am.
Ophthalmol. Soc., 113, T7.
22. Bar-Nun, S. and Glickman, M.H. (2012) Proteasomal
AAA-ATPases: structure and function. Biochim. Biophys. Acta,
1823, 67–82.
23. Farge, G., Mehmedovic, M., Baclayon, M., van den
Wildenberg, S.M., Roos, W.H., Gustafsson, C.M., Wuite, G.J.
and Falkenberg, M. (2014) In vitro-reconstituted nucleoids
can block mitochondrial DNA replication and transcription.
Cell Rep., 8, 66–74.
24. Oppenheim, M.L., Hargreaves, I.P., Pope, S., Land, J.M. and
Heales, S.J. (2009) Mitochondrial cytochrome c release: a fac-
tor to consider in mitochondrial disease? J. Inherit. Metab.
Dis., 32, 269–273.
25. Olahova, M., Hardy, S.A., Hall, J., Yarham, J.W., Haack, T.B.,
Wilson, W.C., Alston, C.L., He, L., Aznauryan, E., Brown, R.M.
et al. (2015) LRPPRC mutations cause early-onset multisys-
tem mitochondrial disease outside of the French-Canadian
population. Brain, 138, 3503–3519.
26. Kereiche, S., Kovacik, L., Bednar, J., Pevala, V., Kunova, N.,
Ondrovicova, G., Bauer, J., Ambro, L., Bellova, J., Kutejova, E.
et al. (2016) The N-terminal domain plays a crucial role in the
structure of a full-length human mitochondrial Lon prote-
ase. Sci. Rep., 6, 33631.
27. Matulis, D., Kranz, J.K., Salemme, F.R. and Todd, M.J. (2005)
Thermodynamic stability of carbonic anhydrase: measure-
ments of binding affinity and stoichiometry using
ThermoFluor. Biochemistry, 44, 5258–5266.
28. Voss, N.R. and Gerstein, M. (2010) 3V: cavity, channel and
cleft volume calculator and extractor. Nucleic Acids Res., 38,
W555–W562.
11Human Molecular Genetics, 2018, Vol. 00, No. 00 |
Downloaded from https://academic.oup.com/hmg/advance-article-abstract/doi/10.1093/hmg/ddy080/4922471
by University of Newcastle user
on 19 April 2018
